KALA Bio shares surge 30.81% premarket after $6M financing led by new CEO David Lazar and $7M debt settlement with Oxford Finance.

KALA Bio surged 30.81% in premarket trading following a $6 million private financing led by newly appointed CEO David Lazar and a $7 million debt settlement with Oxford Finance. These moves averted asset seizure and stabilized the company’s liquidity, with Oxford acquiring a 16.5% stake via 1.62 million shares. The financing and governance shift—Lazar’s leadership—signaled strategic restructuring, though dilution risks and ongoing losses ($7.56M net loss Q3 2025) remain concerns. The premarket rally aligns with the after-hours surge (37.87%), reflecting investor optimism about short-term stability and Lazar’s operational vision, despite unresolved clinical and financial uncertainties.